Evidence map›Paper›PMID 28054988›Full record

ReviewMolecules (Basel, Switzerland)2017

Recent Update on the Role of Chinese Material Medica and Formulations in Diabetic Retinopathy.

Sandeep Vasant More, In-Su Kim, Dong-Kug Choi

Open access · goldAbstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 2 pooled it
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Single herbal medicine for diabetic retinopathy.The Cochrane database of systematic reviews · 2018
    Pooled it
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Ginsenoside Rg1 prevents early diabetic retinopathyAnnals of translational medicine · 2020
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Phytotherapy in the Management of Diabetes: A Review.Molecules (Basel, Switzerland) · 2018
    Review
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Sandeep Vasant MoreDepartment of Biotechnology, Konkuk University, Chungju 380-701, Korea. sandeepbcp@gmail.com.
In-Su KimDepartment of Biotechnology, Konkuk University, Chungju 380-701, Korea. kis5497@kku.ac.kr.
Dong-Kug ChoiDepartment of Biotechnology, Konkuk University, Chungju 380-701, Korea. choidk@kku.ac.kr.
Konkuk University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetes mellitus is one of the most frequent endocrine disorders, affecting populations worldwide. Diabetic retinopathy (DR) is the most frequent microvascular complication of diabetes in patients aged 20 and over. Major complications of DR include intraocular neovascularization, inter-retinal edema, hemorrhage, exudates and microaneurysms. Therefore, timely medical attention and prevention are required. At present, laser-assisted therapy and other operational procedures are the most common treatment for DR. However, these treatments can cause retinal damage and scarring. Also, use of the majority of traditional medicines is not supported by clinical evidence. However, due to accumulating scientific evidence, traditional natural medications may assist in delaying or preventing the progression of DR. This review focuses on evidence for the role of traditional natural medicines and their mechanisms of action and pharmacological test results in relation to the progression of DR.

Indexed as

AdultAnimalsDiabetic RetinopathyDisease ProgressionDrugs, Chinese HerbalHumansMateria MedicaMedicine, Chinese TraditionalNeovascularization, PathologicPlants, MedicinalRetinaDrugs, Chinese HerbalMateria Medicadiabetesherbalmedicineretinopathytraditional

Identifiers

PMID28054988
PMCPMC6155640
OpenAlexW2570195336

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.